Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Non-Current Assets (2022 - 2025)

Entrada Therapeutics has reported Non-Current Assets over the past 4 years, most recently at $71.1 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $71.1 million for Q4 2025, down 17.57% from a year ago — trailing twelve months through Dec 2025 was $308.7 million (down 15.34% YoY), and the annual figure for FY2025 was $71.1 million, down 17.57%.
  • Non-Current Assets for Q4 2025 was $71.1 million at Entrada Therapeutics, down from $74.6 million in the prior quarter.
  • Over the last five years, Non-Current Assets for TRDA hit a ceiling of $103.8 million in Q2 2023 and a floor of $39.7 million in Q3 2022.
  • Median Non-Current Assets over the past 4 years was $81.5 million (2025), compared with a mean of $74.2 million.
  • Biggest five-year swings in Non-Current Assets: surged 156.71% in 2023 and later fell 17.57% in 2025.
  • Entrada Therapeutics' Non-Current Assets stood at $42.2 million in 2022, then surged by 135.7% to $99.4 million in 2023, then dropped by 13.22% to $86.3 million in 2024, then decreased by 17.57% to $71.1 million in 2025.
  • The last three reported values for Non-Current Assets were $71.1 million (Q4 2025), $74.6 million (Q3 2025), and $79.6 million (Q2 2025) per Business Quant data.